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In this issue, Professor Karen Facey and colleagues publish an
important Commentary (p 224) on the use of positron emission
tomography (PET) imaging in cancer management. As they point
out, any novel health technology tends to generate calls for
immediate implementation by clinical enthusiasts, but the case for
investment should be based on a clear evidence of benefit to
patients (rather than to doctors) as well as cost benefit. PET using
fluorine-18 deoxyglucose has given oncologists insight into
tumour metabolism in addition to imaging, and it is a superb
clinical research tool. But should PET imaging become routine?
The Commentary, based on a recent Health Technology
Assessment report, is timely for the UK because the Royal
Colleges Intercollegiate Standing Committee on Nuclear Medicine
earlier this year recommended the development and expansion of
PET imaging. This Committee’s conclusions are almost entirely
devoted to the logistics of implementation, essentially following
American assumptions, without critical appraisal of their utility.
That is why the Health Technology Assessment on PET is so
important.
The authors make two salient points. First, they show that
evidence of accuracy is not directly translatable into cost benefit,
and therefore patient benefit should be recognised as a more
important end point than potential cost saving. Indeed, it is
surprising that although PET imaging was introduced some 20
years ago and has accrued more than 1000 research publications,
patient outcome has not been adequately addressed. Second, the
novel decision modelling scheme developed by these investigators,
which includes the handling of uncertainty, may in this type of
situation provide more useful evidence for policy making than a
randomised controlled clinical trial. No doubt, oncologists will
initially be reluctant to acknowledge this paradigm shift.
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